Thematics Asset Management Sells 842 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Thematics Asset Management reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the third quarter, Holdings Channel.com reports. The fund owned 53,819 shares of the medical research company’s stock after selling 842 shares during the quarter. Thermo Fisher Scientific accounts for 1.3% of Thematics Asset Management’s investment portfolio, making the stock its 19th largest holding. Thematics Asset Management’s holdings in Thermo Fisher Scientific were worth $33,291,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Waverly Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 7.1% during the first quarter. Waverly Advisors LLC now owns 2,386 shares of the medical research company’s stock worth $1,387,000 after purchasing an additional 158 shares during the period. Tidal Investments LLC lifted its stake in Thermo Fisher Scientific by 13.4% in the first quarter. Tidal Investments LLC now owns 16,728 shares of the medical research company’s stock worth $9,718,000 after acquiring an additional 1,972 shares during the period. Beacon Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 39.4% in the 1st quarter. Beacon Capital Management LLC now owns 198 shares of the medical research company’s stock worth $115,000 after acquiring an additional 56 shares in the last quarter. Brown Shipley& Co Ltd boosted its holdings in shares of Thermo Fisher Scientific by 11.8% during the 1st quarter. Brown Shipley& Co Ltd now owns 16,025 shares of the medical research company’s stock valued at $9,254,000 after buying an additional 1,685 shares in the last quarter. Finally, WealthPlan Investment Management LLC increased its stake in shares of Thermo Fisher Scientific by 16.6% in the 1st quarter. WealthPlan Investment Management LLC now owns 2,629 shares of the medical research company’s stock worth $1,528,000 after acquiring an additional 374 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the sale, the chief executive officer now owns 14,608 shares of the company’s stock, valued at approximately $8,076,178.88. This trade represents a 38.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at $9,333,946.08. The trade was a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,150 shares of company stock worth $20,651,865 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.8 %

Shares of TMO stock traded down $4.27 on Tuesday, hitting $509.93. The stock had a trading volume of 278,729 shares, compared to its average volume of 1,496,650. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company has a market cap of $195.05 billion, a PE ratio of 32.23, a P/E/G ratio of 3.39 and a beta of 0.79. The business has a 50 day moving average price of $573.70 and a 200 day moving average price of $579.75. Thermo Fisher Scientific Inc. has a one year low of $480.57 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The business had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company’s revenue was up .2% compared to the same quarter last year. During the same period last year, the business earned $5.69 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has approved a stock repurchase program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on TMO shares. Barclays lowered their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird cut their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Finally, Sanford C. Bernstein decreased their price target on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.